952708-84-8Relevant articles and documents
METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION
-
Paragraph 654; 655, (2019/11/12)
The present disclosure relates to methods of treating cancer comprising administering Parkin ligase activator or a pharmaceutically acceptable salt thereof to a subject who has a mutant form of a protein in the Rb checkpoint pathway. The Parkin ligase activator includes triazole compounds, such as compounds of formula (I), and pharmaceutically acceptable salts thereof as disclosed herein. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.
Synthesis method for thiazole compound with tyrosine kinase inhibitory activity
-
Paragraph 0080; 0081; 0082, (2016/11/17)
The invention relates to a synthesis method for a thiazole compound (I) with tyrosine kinase inhibitory activity. Compound (3) and compound (II) react under the effect of a condensing agent, and thereby the compound (I) is obtained. The synthesis method i
RENIN INHIBITORS
-
Page/Page column 141, (2008/12/04)
Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
